Anti-IgE [EPC]

55462 reported adverse events

Drugs of this class: OMALIZUMAB

These side effects are most commonly reported by patients taking drugs of the Anti-IgE [EPC] class:

# Side effect Count
0 ASTHMA 8958
1 DYSPNOEA 7510
2 URTICARIA 6243
3 DRUG INEFFECTIVE 5272
4 COUGH 5124
5 FATIGUE 4444
6 MALAISE 4082
7 HEADACHE 4021
8 PRURITUS 3949
9 NO ADVERSE EVENT 3925
See all common reactions for Anti-IgE [EPC]

Drugs of the Anti-IgE [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 URTICARIA THERMAL 68 0.6296
1 FORCED EXPIRATORY VOLUME DECREASED 1270 0.5831
2 FORCED EXPIRATORY FLOW DECREASED 45 0.5769
3 CHRONIC SPONTANEOUS URTICARIA 335 0.5766
4 SMOKE SENSITIVITY 116 0.5321
5 PERFUME SENSITIVITY 185 0.4625
6 BRONCHOPULMONARY ASPERGILLOSIS ALLERGIC 280 0.4613
7 BLOOD IMMUNOGLOBULIN E DECREASED 43 0.4095
8 TOTAL LUNG CAPACITY INCREASED 67 0.4085
9 EXPOSURE TO ALLERGEN 56 0.3684
See all enriched reactions for Anti-IgE [EPC]